RESEARCH TRIANGLE PARK, NC--(Marketwire - September 12, 2008) - The finding comes out of a new
study released by market intelligence firm Cutting Edge Information.
According to the study, total oncology sales will grow by 22% between 2007
and 2010, to reach $77 billion by 2010. The market will then continue to
expand to surpass $90 billion by 2013
(
http://www.cuttingedgeinfo.com/oncology/TA220_Download.asp).
With a plethora of innovative treatments in the pipeline, it is not
surprising that the oncology market is projected to grow so dramatically.
According to Cutting Edge Information, the most notable growth will come
from the class of monoclonal antibodies (MAbs), which already contains
several multi-billion dollar drugs, including Roche's and Genentech's
Avastin and Herceptin and Roche's Rituxan. Additional growth from these
existing blockbusters, combined with the launch of many new promising
therapies, will contribute to continued success for this class of drugs and
for the oncology market as a whole.
According to Cutting Edge Information, the challenge for life sciences
companies is to manage ever-increasing development costs for the cancer
therapies in their pipelines while still communicating value to key
stakeholders such as healthcare payers. Cost efficiency and marginal
outcomes improvements are more important than ever before in winning over
customers in the oncology market. Despite these hurdles, companies'
oncology pipelines look very promising.
"The oncology market is poised to grow substantially through 2013 and
beyond," said Eric Bolesh, lead author of the study. "We are seeing a
surge in innovative new treatments, many of which will launch over the next
four to five years."
The new report, "The Oncology Market Forecast to 2013," is a comprehensive
study of more than 135 oncology drugs. It includes analysis of findings
presented at the annual meeting of the American Society of Clinical
Oncology (ASCO) and provides the following:
-- Individual Drug Profiles -- Drug profiles include information about
drugs' competitive, strategic and market growth positions.
-- Oncology Indication Market Outlook -- Detailed outlooks for the
breast, colorectal, lung and prostate cancer and leukemia markets.
-- Company Profiles -- Oncology breakdowns for companies that either have
established oncology franchises or exciting development pipelines for new
cancer compounds.
A complimentary brochure for the report is available for immediate download
here:
http://www.cuttingedgeinfo.com/oncology/TA220_Download.asp
Contact Information: CONTACT INFORMATION:
Eric Bolesh
919-433-0209